- Home
- PULM vs ANTX Comparison
PULM vs ANTX Comparison
Compare PULM & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- ANTX
- Stock Information
- Founded
- PULM 2003
- ANTX 2017
- Country
- PULM United States
- ANTX United States
- Employees
- PULM N/A
- ANTX N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- ANTX Health Care
- Exchange
- PULM Nasdaq
- ANTX Nasdaq
- Market Cap
- PULM 20.5M
- ANTX 33.2M
- IPO Year
- PULM N/A
- ANTX 2022
- Fundamental
- Price
- PULM $5.57
- ANTX $1.07
- Analyst Decision
- PULM
- ANTX Buy
- Analyst Count
- PULM 0
- ANTX 2
- Target Price
- PULM N/A
- ANTX $2.00
- AVG Volume (30 Days)
- PULM 10.9K
- ANTX 71.9K
- Earning Date
- PULM 08-12-2025
- ANTX 08-12-2025
- Dividend Yield
- PULM N/A
- ANTX N/A
- EPS Growth
- PULM N/A
- ANTX N/A
- EPS
- PULM N/A
- ANTX N/A
- Revenue
- PULM $1,921,000.00
- ANTX N/A
- Revenue This Year
- PULM N/A
- ANTX N/A
- Revenue Next Year
- PULM $134.88
- ANTX N/A
- P/E Ratio
- PULM N/A
- ANTX N/A
- Revenue Growth
- PULM N/A
- ANTX N/A
- 52 Week Low
- PULM $1.78
- ANTX $0.87
- 52 Week High
- PULM $10.40
- ANTX $2.73
- Technical
- Relative Strength Index (RSI)
- PULM 36.25
- ANTX 45.56
- Support Level
- PULM $5.20
- ANTX $1.05
- Resistance Level
- PULM $6.15
- ANTX $1.16
- Average True Range (ATR)
- PULM 0.30
- ANTX 0.03
- MACD
- PULM -0.05
- ANTX 0.00
- Stochastic Oscillator
- PULM 22.70
- ANTX 18.87
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.